ARS Pharmaceuticals (SPRY) Receivables - Other (2021 - 2025)
ARS Pharmaceuticals (SPRY) posted Receivables - Other of $4.3 million for Q3 2025, up 110.61% sequentially from $2.0 million in Q2 2025, and up 3109.77% YoY from $133000.0 in Q3 2024.
ARS Pharmaceuticals (SPRY) Receivables - Other (2021 - 2025) Analysis & Trends
ARS Pharmaceuticals has reported Receivables - Other for 5 years, with the latest figure at $4.3 million in Q3 2025.
- Quarterly Receivables - Other rose 3109.77% year-over-year to $4.3 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $4.3 million (up 3109.77% YoY) and the FY2024 annual result came in at $1.2 million, up 88.96% from the prior year.
- Receivables - Other advanced to $4.3 million in Q3 2025 per SPRY's latest filing, from $2.0 million in the prior quarter.
- Over five years, Receivables - Other peaked at $4.3 million in Q3 2025 and troughed at $122000.0 in Q2 2024.
- A 5-year average of $839538.5 and a median of $307000.0 in 2023 frame the typical range for Receivables - Other.
- The sharpest annual moves came in 2024 and 2025: Receivables - Other plunged 65.04% in 2024, then surged 3109.77% in 2025.
- Over 5 years, Receivables - Other stood at $159000.0 in 2021, then soared by 33.96% to $213000.0 in 2022, then jumped by 206.1% to $652000.0 in 2023, then soared by 88.96% to $1.2 million in 2024, then soared by 246.51% to $4.3 million in 2025.
- According to Business Quant data, Receivables - Other over the past three periods registered $4.3 million, $2.0 million, and $963000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 4.27 Mn |
| Sep 30, 2025 | 4.27 Mn |
| Jun 30, 2025 | 2.03 Mn |
| Jun 30, 2025 | 2.03 Mn |
| Mar 31, 2025 | 963,000.00 |
| Mar 31, 2025 | 963,000.00 |
| Dec 31, 2024 | 1.23 Mn |
| Dec 31, 2024 | 1.23 Mn |
| Sep 30, 2024 | 133,000.00 |
| Sep 30, 2024 | 133,000.00 |
| Jun 30, 2024 | 122,000.00 |
| Jun 30, 2024 | 122,000.00 |
| Mar 31, 2024 | 280,000.00 |
| Mar 31, 2024 | 280,000.00 |
| Dec 31, 2023 | 652,000.00 |
| Dec 31, 2023 | 652,000.00 |
| Sep 30, 2023 | 208,000.00 |
| Sep 30, 2023 | 208,000.00 |
| Jun 30, 2023 | 349,000.00 |
| Jun 30, 2023 | 349,000.00 |